FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number:	3235-0287				
stimated average burden					
ours per response	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

e Response		*						~		5 D.1-41- 1	: cD '	D() :	- T	
			2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]				(Check all applicable) Director10% Owner XOfficer (give title below)Other (specify below)							
RO PLAC	E NORTH, SUIT		3. Date of Earliest Transaction (Month/Day/Year) 02/15/2013				SVP, C	FO, Treas & S	secy					
OH 4201	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person								
OH 4301	(State)	(Zip)			Tab	le I -	Non-Deri	vative Securit	ies Acqui	red. Dispose	d of, or Bene	eficially Owne	ed	
curity		2. Transaction Date (Month/Day/Year)	Executi any	on D	Date, if Co	ode nstr. i	8) (A) or Disposed Instr. 3, 4 and	1 of (D) (5)	Owned Follo Fransaction(s	wing Reporte)	ed C	Ownership of Form: Direct (D) or Indirect (I)	Nature Indirect eneficial wnership nstr. 4)
							form d	isplays a cu osed of, or Be	rrently v neficially	alid OMB o				
le of 2. Conversion Oate (Month/Day/Year) 3. Transaction Date Execution Date, if Oreivative Security 3. A. Deemed Execution Date, if Ocode Security 3. A. Deemed Execution Date, if Ocode Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Instr. 8) (Month/Day/Year)		5. Number of 6. Date Exercisable and 7. Title Derivative Expiration Date (Month/Day/Year) 5. Securities (Month/Day/Year) 5. Securities 5. Number of 6. Date Exercisable and 7. Title of Und.				nderlying Derir rities Secu		Derivative Securities Beneficially Owned Following Reported	Ownership of Form of Derivative Security: Direct (D) or Indirect	Beneficial				
	Code	v	(A)	(D)	Date Exercisab	Expiration Date	Title	Amount or Number of Share		(Instr. 4)	(Instr. 4)			
	OPLAC OH 4301 curity eport on a second rescriberative of Derivative	OPLACE NORTH, SUIT (Street) OH 43017 (State) curity as separate line for each conversion of the Exercise of Derivative Separate line for each conversion of the Exercise of Derivative of Derivative	Conversion reservice of Perivative OPLACE NORTH, SUITE 450 (Street) OH 43017 (State) (Zip) 2. Transaction Date (Month/Day/Year) Table II - (Conversion Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year)	PRENT L (First) (O PLACE NORTH, SUITE 450 (Street) (Street) (State) (State) (State) (Zip) Curity (State) (Zip) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) Table II - Derivation (e.g., put (e.g., put (Month/Day/Year)) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8)	PRENT L (First) (Middle) (DAVB] (OPLACE NORTH, SUITE 450 (D2/15/2013) (Street) (Street) (A. If Amendment of Execution Date (Month/Day/Year) (State) (Zip) (Zip) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day (Month/Day (Month/Day (Month/Day (Month/Day (Month/Day/Year))) Table II - Derivative Sec.g., puts, can (Month/Day/Year) (Instr. 8)	PRENT L (First) (O PLACE NORTH, SUITE 450 (Street) (Street) (Street) (State) (State) (Zip) (A. If Amendment, Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A. Deemed Execution Date, if Clar any (Month/Day/Year) (Month/Day/Year) (C.g., puts, calls, warranger) (Month/Day/Year) (Month/Day/Year)	PRENT L (First) (Middle) (Department) (Street) (OPLACE NORTH, SUITE 450 (OZ/15/2013 (Street)) (OPLACE NORTH, SUITE 450 (OZ/15/2013 (Street)) (OPLACE NORTH, SUITE 450 (OZ/15/2013 (A. If Amendment, Date Original Content of Code (Instr. 3) (Month/Day/Year) (State) (Zip) Table I - Derivative Securities Acquive (e.g., puts, calls, warrants, and conversion of Exercise (Month/Day/Year) (Month/Day/Year) (State) (Zip) Table I - Derivative Securities Acquive (e.g., puts, calls, warrants, and conversion of Execution Date, if Code (Instr. 4) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Ozerivative Securities Acquived (A) or Disposed of (D) (Instr. 3, 4, 4)	PRENT L NAVIDEA BIOPHARMACEUT [NAVB]	NAVIDEA BIOPHARMACEUTICALS, INC [NAVB] 3. Date of Earliest Transaction (Month/Day/Year) 02/15/2013 (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (State) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 24. Deemed Execution Date, if (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 25. Transaction Date, if (Instr. 8) (Instr. 8) (Instr. 8) (Instr. 8) (Instr. 8) Persons who respect ontained in this form displays a cu Table II - Derivative Securities Acquired, Disposed of, or Be (e.g., puts, calls, warrants, options, convertible seed of (D) (Instr. 3, 4, and 5) Date Expiration Date Expiration Date Expiration	BRENT L (First) (Middle) (O PLACE NORTH, SUITE 450 (Street) (State) (State) (Zip) (Zip) (A) Date (Month/Day/Year) (State) (A) Table I - Non-Derivative Securities Acquired (A) or Price (A) Amount (D) Price (A) Amount (D) Price (B) Persons who respond to the contained in this form are a form displays a currently vecurity (Month/Day/Year) (A) O PLACE NORTH, SUITE 450 (State) (State) (Zip) (Zip) (Zip) (Zip) (Zip) (Zip) (A) Date (A) Or Disposed of (D) (Instr. 3, 4 and 5) (A) Or Price (A) Or Price (A) Or Or Beneficially owned directly or indirectly. (A) Or Price (A) Or Or Beneficially (A) Or Or Beneficially (A) Or Or Disposed of (D) (Instr. 3, 4, and 5) (Month/Day/Year) (A) Or Price (A) Or Beneficially (A) Or Derivative (A) Or Disposed of (D) (Instr. 3, 4, and 5) (Month/Day/Year) (Instr. 3, 4, and 5) (Month/Day/Year) (Month/Day/Year)	BRENT L NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] Director X Officer (g X Office	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] SUrector X Officer (give title below) SVP, C	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] OPLACE NORTH, SUITE 450 OPLA	BRENT L NAVIDEA BIOPHARMACEUTICALS, INC. Director 10% Owner 10% Owner

D (O N / /)	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
LARSON BRENT L 425 METRO PLACE NORTH SUITE 450 DUBLIN, OH 43017			SVP, CFO, Treas & Secy			

Signatures

William J. Kelly, Jr., Attorney-In-Fact	02/19/2013
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option vests 25% per year beginning on the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.